GP-100 ANTIGEN

Summary

Gp-100 Antigen (CHEMBL4297963) is a phase-3 clinical-stage unknown; indicated across 4 conditions including cutaneous melanoma and melanoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 38

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297963
Name	GP-100 ANTIGEN
Type	Unknown
Max phase	3

Also known as: Gp-100 antigen, Gp100 antigen, Gp100 glycoprotein, Melanocyte protein pmel, Melanocyte protein pmel 17, Melanoma-associated me20 antigen, Premelanosome protein, GP-100 ANTIGEN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cutaneous melanoma	3	MONDO:0005012	EFO:0000389
melanoma	3	MONDO:0005105	EFO:0000756
ocular melanoma	3	MONDO:0006325	EFO:1000403

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 38.

Phase distribution

Phase	Trials
PHASE2	23
PHASE1	9
PHASE1/PHASE2	3
PHASE3	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00019682	PHASE3	COMPLETED	Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
NCT00036816	PHASE3	TERMINATED	Vaccine Therapy in Treating Patients With Melanoma of the Eye
NCT00003222	PHASE2	COMPLETED	Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
NCT00003229	PHASE1/PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal
NCT00003274	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery
NCT00003339	PHASE2	COMPLETED	Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
NCT00003362	PHASE2	COMPLETED	Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma
NCT00003568	PHASE2	COMPLETED	Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00006113	PHASE2	TERMINATED	Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00006385	PHASE2	COMPLETED	Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
NCT00010309	PHASE1/PHASE2	UNKNOWN	Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma
NCT00019214	PHASE1/PHASE2	COMPLETED	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00019396	PHASE2	COMPLETED	flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
NCT00019448	PHASE2	COMPLETED	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00019669	PHASE2	COMPLETED	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00019721	PHASE2	COMPLETED	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00019994	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00020358	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Melanoma
NCT00020475	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
NCT00031733	PHASE2	COMPLETED	Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
NCT00032045	PHASE2	COMPLETED	Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
NCT00072085	PHASE2	COMPLETED	Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
NCT00077532	PHASE2	COMPLETED	Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma
NCT00085189	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
NCT00085397	PHASE2	UNKNOWN	Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00089063	PHASE2	COMPLETED	Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
NCT00295958	PHASE2	COMPLETED	LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery
NCT00303836	PHASE2	TERMINATED	Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma
NCT00003665	PHASE1	COMPLETED	Vaccine Therapy in Treating Patients With Stage IV Melanoma
NCT00003792	PHASE1	COMPLETED	Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00003897	PHASE1	COMPLETED	Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma
NCT00005841	PHASE1	TERMINATED	Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00019175	PHASE1	COMPLETED	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma
NCT00025181	PHASE1	COMPLETED	Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
NCT00091143	PHASE1	COMPLETED	Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma
NCT00091338	PHASE1	COMPLETED	Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00470015	PHASE1	COMPLETED	Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma
NCT00006243	Not specified	COMPLETED	Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).